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Many drugs are effective in the early stage of treatment, but patients develop drug resistance after a certain
period of treatment, causing failure of the therapy. An important example is Herceptin, a popular
monoclonal antibody drug for breast cancer by specifically targeting human epidermal growth factor
receptor 2 (Her2). Here we demonstrate a quantitative binding kinetics analysis of drug-target interactions
to investigate the molecular scale origin of drug resistance. Using a surface plasmon resonance imaging, we
measured the in situ Herceptin-Her2 binding kinetics in single intact cancer cells for the first time, and
observed significantly weakened Herceptin-Her2 interactions in Herceptin-resistant cells, compared to
those in Herceptin-sensitive cells. We further showed that the steric hindrance of Mucin-4, a membrane
protein, was responsible for the altered drug-receptor binding. This effect of a third molecule on
drug-receptor interactions cannot be studied using traditional purified proteinmethods, demonstrating the
importance of the present intact cell-based binding kinetics analysis.
T
he effectiveness of drugs relies on their specific binding with disease-related receptors1,2. For this reason,
determining the drug-receptor binding kinetics has been a major task in drug design and screening3,4.
Unfortunately, many drugs are effective only in the early stage of treatment, and patients develop drug
resistance over time, causing failure of the therapy. An important example isHerceptin, one of themost successful
drugs on the market for treating human epidermal growth factor receptor 2 (Her2) positive breast cancer5,6. The
drug inhibits the growth of tumor by binding to overexpressed Her2 in the tumor cell membrane, but most
patients develop drug resistance after a short period of treatment5,6. Determining amolecular-scale mechanism of
drug resistance is critical to the quest for solutions for drug resistance7. Given the importance of drug-receptor
binding in drug actions, it is reasonable to ask: Is the drug resistance caused by the loss or weakening of drug-
receptor binding due to steric hindrance8,9 and allosteric modulation10–12 by adjacent molecules (alternation
hypothesis), or is it due to the development of alternative signaling pathways (bypass hypothesis)13–15?
We hypothesized that in situ binding kinetics analysis in intact cells would provide a direct answer to this
question, because the ‘‘alternation hypothesis’’ would mean a large change in the binding behaviors of drugs with
the receptors in drug-resistant cells while the ‘‘bypass hypothesis’’ would imply no change in the binding kinetics
(Fig. 1). Such information cannot be obtained by traditional binding kinetics studies thatmeasure the interactions
of drugs with purified membrane receptors immobilized on a solid surface. This is because the purification
process isolates the receptors from the native cellular environment where binding modulators are located or
bypass pathway developed, and the immobilization may affect the drug-receptor interactions.
Here we report a single cell-based quantitative analysis of drug-receptor binding kinetics to investigate the
molecular scale origin of drug resistance. We measured the in situ binding kinetics of Herceptin with Her2 in
single intact cultured cells and primary cells extracted from breast tumor tissues for the first time with a high
resolution surface plasmon resonance (SPR) imaging technique. By doing so, we observed significantly weakened
Herceptin-Her2 interactions inHerceptin-resistant resistant cells, compared to those inHerceptin-sensitive cells.
Furthermore, we found that the steric hindrance ofMucin-4, a membrane protein, was responsible for the altered
drug-receptor binding. This alternation of drug-target interactions by a third molecule in the surrounding
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environment cannot be observed and studied with the traditional
purified protein-based SPR methods, demonstrating the importance
of the present intact cell-based binding kinetics analysis.
To date, in situ study of drug-receptor binding in intact cells has
been limited to fluorescence labeling-based assays. A popular fluor-
escence method is kinetic exclusion assay, which measures the con-
centration of free drugs remaining in the supernatant after the
binding equilibrium in cell suspension is achieved16–18. This is an
end-point assay, and not suitable for extracting the kinetic constants.
Furthermore, the use of fluorescent labels is not only labor intensive
but may also affect the binding behaviors. Label-free technology,
such as SPR, has been developed for studying the binding kinetics
of purified proteins in pre-clinical drug screening19,20. We have
shown that the interactions of lectin with glycoproteins in single cells
can be studied with a SPR imaging setup21. However, the setup lacks
the sensitivity and stability to monitor the binding of drugs to low
abundance of endogenous receptors.
The imaging setup (Fig. 2A) in the present work performs signifi-
cantly better than the one used in our previous work21, making it
possible to study drug binding to endogenous receptors in single
cells. The performance improvement was mainly due to optimized
light source and implementation of a temperature control system,
and mechanical noise reduction stage system. The new setup pro-
vides 9 times smaller short-term noise (Fig. 2B), and 11 times smaller
long-term drift (Fig. 2C) than those in the previous report21.
Fig. 2D shows a typical SPR image of individual SK-BR3 cells
attached on gold-coated coverslip. SK-BR3 is a widely used breast
cancer cell line and known to express Her2 endogenously in the cell
membranes. The overexpression of Her2 in the cell line was further
verified by immunofluorescence staining (Supplementary Infor-
mation). Note that the adherent cells were fixed by 4% paraformalde-
hyde prior to experiment to minimize the intrinsic micromotions of
the cells. To measure the binding kinetics of Herceptin with Her2,
PBS buffer was first introduced to flow over the SK-BR3 cells on the
surface, and Herceptin dissolved in PBS buffer was then introduced
to bind to the cells. After the binding (association) process, PBS
buffer was re-introduced to flow over the cells for studying the dis-
sociation process. The entire association and dissociation processes
were imaged with the SPR setup, from which sensorgrams of the
individual cells were obtained to determine the kinetic constants.
Upon introducing Herceptin, the image intensity in the cell
regions increased, indicating the binding of Herceptin toHer2 recep-
tors in the membrane of SK-BR3 cells. The black line in Fig. 2E is an
averaged sensorgram over 30 cells, which shows clearly the asso-
ciation (rising) and dissociation (falling) processes of Herceptin on
Her2 expressing SK-BR3 cells. The gray background reflects the
statistical deviation among all cells. The binding kinetics of
Herceptin to SK-BR3 cells can be determined by fitting the average
sensorgram based on a 151 Langmuir bindingmodel, which is shown
by the red curve in Fig. 2E. The corresponding association (kon) and
dissociation rate constants (koff) were found to be 1.7 3 105 M21s21
and 3.3 3 1024 s21, respectively, from which the equilibrium con-
stant (KD) was determined as 1.9 nM. This value is close to the
literature report in which Her2-expressing living cells were also
used22. No significant intensity change was observed in the regions
without the cells (Fig. 2E), indicating the absence of non-specific
adsorption of Herceptin to gold regions.
In order to further quantify the variability in the binding kinetics,
the Langmuir binding model was used to fit the SPR sensorgram of
each individual cell. The histograms of kon, koff andKD for 60 cells are
shown in Supplementary Information Section 1. The average kinetic
constants are generally consistent with those obtained by fitting the
average sensorgram, but the values vary among different cells.
Concentration-dependent kinetic measurement was carried out
by sequentially increasing the Herceptin concentration from 0.42
to 21 mg/mL. Note that the cell surface was regenerated for each
change of concentration by introducing 100 mM NaOH for 30 sec-
onds (Supplementary Information Section 2). The family of sensor-
grams at different Herceptin concentrations, as shown in Fig. 2F, can
be fit globally based on the 151 Langmuir binding model (red
curves), and the corresponding kinetic constants, kon, koff and KD
are 1.93 105 M21s21, 2.33 1024 s21 and 1.2 nM, respectively. These
values are in good agreement with the kinetic constants obtained by
fitting each of the individual sensorgrams separately, which further
validate the 151 Langmuir binding model.
In order to further verify that the SPR binding signal was from the
specific interaction between Herceptin drug and the surface-bound
Her2 receptors, twoHer2-positive (BT474 andMCF7-Her2) and two
Her2-negative (MCF7-WT and HeLa) cell lines were included as
positive and negative controls, respectively. Like SK-BR3, BT474 is
another well-known breast cancer cell line that endogenously over-
expresses Her2 in its cell membrane. MCF7-Her2 was developed
from Her2-negative wildtype MCF7 cells (MCF7-WT) via gene
transduction to stably overexpress Her2, leading to an engineered
Her2-positive cell line23. In order to evaluate possible non-specific
adsorption of Herceptin onto the cell membrane, Her2-negative
MCF7-WT and HeLa, a human epithelial carcinoma cell line, were
selected as negative controls. The Her2 expression levels in these cell
lines were subsequently validated by the immunofluorescence stain-
ing against Her2 (Supplementary Information Section 3).
Herceptin-binding kinetics measurement, similar to those per-
formed for SK-BR3 described above, was performed for each of the
cell lines. The average sensorgrams (black curves), and standard
deviations (gray background) of BT474 and MCF7-Her2 are shown
in Figs. 3A and 3B, respectively. For comparison, the sensorgrams
from the negative control cell lines, HeLa (Fig. 3C) and MCF7-WT
(Fig. 3D) show flat lines with no sign of Herceptin binding. The
sensorgrams for BT474 and MCF7-Her2 can be fit with the 151
Langmuir binding model (red curve). The kinetic constants deter-
mined from the fitting are listed in Table 1 together with those
obtained for SK-BR3 for comparison. An important observation is
that the kinetic constants of different cell lines differ by 5 folds, which
Figure 1 | Top: Under ‘‘bypass hypothesis’’, in situ binding kinetics of
Herceptin with resistant cell was not affected. Bottom: ‘‘Alternation
hypothesis’’ suggests an altered binding kinetics due to the influences of
relevant proteins surrounding Her2.
www.nature.com/scientificreports
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indicates influences of environments on drug-receptor interactions.
Previous studies showed that the binding affinity of Herceptin with
intact Her2-containing cell membrane was 50 times weaker than that
of Herceptin with free extracellular domain of Her2 in solution22.
Molecular interactions occurring at the solution-membrane inter-
face are known to highly depend on membrane properties, such as
surface charge, polarity and curvature24. Moreover, cell membrane
components that are adjacent to Her2 might also strengthen or
weaken its interaction with Herceptin via a positive or negative
cooperativity, respectively10–12.
The unique capability for determining drug-receptor binding
kinetics in intact cells was applied to study Herceptin resistance
mechanism by comparing the Herceptin binding kinetics of
Herceptin-sensitive with that of Herceptin-resistant cells. Two
Herceptin-sensitive (C11 and E8) and two Herceptin-resistant (H6
and C5) SK-BR3 clones were studied (Supplementary Information
Section 5) at a Herceptin concentration of 2.1 mg/mL, which is rel-
evant to the drug concentration in the body used in clinical therapy.
The sensorgrams of the four clones are shown in Fig. 4A. The
Herceptin-resistant clones, H6 and C5, exhibit two distinct dissoci-
ation processes, a fast process followed by a slow process (Figs. 4A,
H6 and C5). This behavior is completely different from the dissoci-
ation processes in the Herceptin-sensitive clones (Figs. 4A, E8 and
C11) and in the other Her2-positive cell lines (Figs. 2D, 3A and 3B),
which follow the simple single dissociation kinetics.
The two dissociation processes of SK-BR3 H6 and C5 clones can
be fit with two exponential functions, each with a different dissoci-
ation constant. The kinetics constants of the slow process are listed in
Table 1, which are comparable with the dissociation constants of
Herceptin-sensitive cells. It indicates that Herceptin remains effec-
tive for this population of Her2, which will be thus referred to as the
effective population. In contrast, the fast dissociation process is tens
of times faster than that found for the regular Herceptin-sensitive
cells, indicating the binding ofHerceptin to this population ofHer2 is
greatly weakened in the Herceptin-resistant clones. Consequently,
the bound Herceptin has much shorter residence time and can be
quickly washed off. This population is expected to be ineffective for
Herceptin treatment, andwill be referred to as ineffective population.
Figure 2 | A) Experimental setup. A p-polarized LED light is directed onto a gold-coated glass slide mounted on a SF-11 prim to create SPR on the gold
surface, which is capturedwith a CCD camera. In situ binding kinetics can be extracted from the time lapse SPR imagewhen drug flown over a cell adhered
on the gold chip. (B) Short-term noise level when using a superluminescent (SLD, red curves) and a light emitting diode (LED, black curves) as light
source. (C) Long-term noise level for a LED light source with and without temperature control. D) Typical SPR image of a few tens of SK-BR3 cells
adhered on a gold-coated coverslip. E) The SPR sensorgrams of each individual cells (black: average SPR sensorgram, red: fitted curve, grey background:
cell-to-cell variation) and the surrounding regions without cell coverage (blue curve). F) The concentration-dependent SPR sensorgrams and global
fitting (red curves). The Herceptin concentration was 21, 8.4, 4.2, 2.1, 1.05 and 0.42 mg/mL from top to bottom curve, respectively. Scale bar, 100 mm.
www.nature.com/scientificreports
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The sensorgrams from the individual cells exhibit a large variabil-
ity in the binding kinetics as shown by the gray area in Fig. 4A,
indicating that the degree of Herceptin-resistant is different for dif-
ferent cells. This heterogeneity can be quantified with a resistance
index (RI) based on the drug binding kinetics, which is the ratio of the
weakly bound Herceptin (the ineffective population of Her2) to all
the bound Herceptin, including both weakly and strongly bound
drug molecules (both ineffective and effective populations of
Her2). When RI 5 1, all the drug molecules are weakly bound to
the cell, and the cell is most drug resistant. On the other hand, when
RI 5 0, all the drug molecules are strongly bound to the cell, and the
cell is least drug resistant (Supplementary Information Section 6).
RI for each of the individual cells was mapped from the SPR
intensities at the end of association and 10minutes after dissociation.
The former is proportional to the total bound Herceptin on the cell,
and latter reflects the population of the strongly bound Herceptin.
Figs. 4B show drug resistant maps of individual cells for H6, C5, E8
and C11, where each spot reflects the morphology of a single cell and
the color of each cell represents the RI value. From the maps, the
average RI values of H6, C5, E8 and C11 were determined to be 0.78
6 0.11, 0.58 6 0.09, 0.31 6 0.18, and 0.29 6 0.13, respectively, from
which the degree of Herceptin resistance of these clones is in the
order of H6.C5. E8<C11. From the colors of the individual cells
for each clone in Fig. 4B, the large cell-to-cell variability in the
Herceptin-binding within the same clone can be easily visualized.
More detailed analysis of the variability in the binding kinetics is
shown in Fig. 4C, which plot the sensorgrams of two exemplary cells
for each of the clones.
It has been pointed out that the Herceptin binding sites of Her2 in
the Herceptin-resistant cells were probably blocked by certain mem-
brane proteins, such as Mucin-4 (MUC4)8. However, a specialized
cell line was used in that research and no direct evidence on the
altered binding kinetics was provided. Further more, the end-point
fluorescence assay could not identify the ineffective population
because the drug can be easily washed off. The kinetics study here
suggests the co-existence of two populations, and that the binding
sites are still available for Herceptin, however, the bound Herceptin
to these binding sites dissociates quickly.
In order to examine the role of MUC4 in the ineffective popu-
lation, the following experiments were carried out. 1) The expression
levels of MUC4 of H6, C5, E8 and C11 were determined by immuno-
fluorescence staining (Fig. 5A). The results show that the MUC4
expression levels in the Herceptin-resistant clones are indeed much
higher than those in the Herceptin-sensitive clones (Supplementary
Information Section 7). 2) The abundance levels of Her2 in all the
clones were studied with immunofluorescence staining by using
another anti-Her2 polyclonal antibody that recognizes different
binding sites in Her2. The results confirm the finding from the
SPR kinetic data that overall Her2 expression level does not signifi-
cantly decrease in Herceptin-resistant clones (Supplementary
Information Section 8). 3) Dual-staining of Her2 (using Herceptin
as primary antibody) and MUC4 for a given Herceptin-resistant C5
clone was carried out (Fig. 5B and Supplementary Information
Section 9), showing that the regions with more MUC4 tend to have
less Herceptin bound to Her2, and vice versa. Such negative co-
localization was observed in lots of the studied cells with varied
Figure 3 | SPR sensorgrams when introducing 2.1 mg/mL Herceptin over A) BT474, B) MCF7-Her2, C) HeLa and D) MCF7-WT, respectively.
Table 1 | Binding kinetics parameters of different cell lines and
clones
Cell/Clone kon 1 3 105 M21s21 koff 13 1024 s21 KD nM
SK-BR3 1.3 6 0.4 3.4 6 2.6 2.7 6 2.0
BT474 6.2 6 2.2 4.0 6 2.4 0.7 6 0.4
MCF7-Her2 3.6 6 1.0 9.1 6 4.3 2.5 6 1.6
SK-BR3 (H6)[a] 2.1 6 1.0 5.4 6 2.2 3.1 6 2.5
SK-BR3 (C5)[a] 1.3 6 0.3 5.9 6 2.6 5.5 6 3.5
SK-BR3 (E8) 7.4 6 2.1 3.6 6 1.5 0.5 6 0.2
SK-BR3 (C11) 3.5 6 1.7 2.4 6 0.9 0.7 6 0.3
[a]Only the effective Her2 population was listed here.
www.nature.com/scientificreports
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extents, this particular cell shown in Fig. 5B was selected for best
presentation. Note that the Her2 staining result in Fig. 5B (green)
only represents the distribution of effective Her2 population rather
than the total Her2 population, since those regions with ineffective
Her2 populationwould lose all theHerceptin during the rinsing stage
in the assay. The present study suggests that MUC4 interacts with
some of the Her2 in the drug resistant cells, which weakens the
binding of Herceptin to Her2. This is believed to be associated with
the ineffective Her2 population observed in the SPR sensorgrams.
The experimental data in the present work are consistent with the
alternation hypothesis. Additional studies are needed to further elu-
cidate the mechanism.
In conclusion, a single cell-based kinetic analysis approach was
developed to elucidate the molecular scale origin of drug resistance.
The approach uses a label-free SPR imaging technique to image and
quantify the interactions of drugs with low abundance endogenous
receptors in intact cells. Using the approach, the binding kinetics of
Herceptin, an anti-tumor drug, with its receptor, Her2, in both drug-
sensitive and drug-resistant cells were quantified. The study revealed
two distinct populations of Her2 in the Herceptin-resistant cells. The
first one has binding kinetics similar to that of Herceptin-sensitive
cells, but the second population has a dissociation process tens of
times faster, indicating a short residence time of bound Herceptin.
The presence of the second population is likely responsible for the
drug-resistance. This important information is not available from
any other studies carried out to date. The method and technique
developed here are expected to be applicable to study other drug-
receptor interactions for screening of drugs, and for elucidation of
drug resistance mechanism.
Methods
Materials. Herceptin was obtained from Genentech Inc. (San Francisco, CA) as
powder. The Herceptin stock solution was prepared by dissolving 42 mg powder in
1 mL pure water, reaching an effectivemAb concentration of 21 mg/mL by following
the manufacturer’s instruction. The Herceptin solution used in the present work was
prepared by correspondingly diluting the stock solution with PBS. 4%
Paraformaldehyde was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA). Alexa Fluor 488 goat anti-human IgG1 (c1), Alexa Fluor 555 goat anti-mouse
IgG1 (c1) and MUC4 mouse mAb (clone 1G8) were purchased from Invitrogen Inc.
(Carlsbad, California). All the reagents were analytical grade and purchased from
Sigma-Aldrich, except where otherwise stated. Deionized water was used to prepare
all the buffers.
Figure 4 | Herceptin interactions with SK-BR3 Herceptin-resistant (H6 and C5) and SK-BR3 Herceptin-sensitive (E8 and C11) clones. A) The
average SPR sensorgram of each clone and the corresponding two-constant (H6 and C5) or one-constant (E8 and C11) fitting. B) The resistance index
(RI) map of each clone, demonstrating the potency of individual cell being resistant to Herceptin treatment. C) SPR sensorgrams of two individual cells
are shown to demonstrate the cell-to-cell variation when interacts with Herceptin. Scale bars, 100 mm.
www.nature.com/scientificreports
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SK-BR3 Herceptin sensitive and resistant clones selection. SK-BR3 Herceptin
sensitive and resistant clones were developed by Dr. Laura Gonzalez in LaBaer’s lab.
In brief, SK-BR3 cells were diluted in order to have at least one cell/well and plated
into 10 plates of 96 multiwells and grown for approximately one month. When cells
reach confluence, they were trypsinized and condensed into 2 plates. After
condensing all the subclones that grew, they were grown again to confluence and split
into 3 different plates: one as archive, one as a control and the last one treated with
Herceptin. After 6 days post-treatment, cell proliferation was measured by resazurin.
When survival of cells was inhibited by at least 50% compared to non-treated cells, we
considered them as Herceptin-sensitive, whereas if cells continue to grow in presence
of Herceptin with numbers at least 80% of those for non-treated cells, we consider
them as Herceptin-resistant (Fig. S5).
MCF7-Her2 transfection. Retroviral particles were prepared to transduce MCF7
cells to stably express Her2, as described before23. In brief, packaging cell line HEK
293T was transfected with high quality plasmid DNA of retroviral construct
(pJP1520-Her2), mixed with two other plasmids (retroviral gag-pol and VSV-G).
Virus was then harvested daily for 4 days, aliquoted and storage at -80uC. ThenMCF7
cells were seeded in 6 well format plates and transduced using these retroviruses
which has puromycin acetyl transferase gene to allow the selection of infected cells.
Cells were kept in the presence of puromycin (1 mg/ml) until reach confluence and
expanded in bigger flasks until stable cell line was established.
Cell line culture. SK-BR3, BT-474, MCF7-WT cell lines were kindly provided by Dr.
LaBaer and HeLa cell line was obtained from the American Type Culture Collection
(Rockville,MD). All the cells were cultured in a humidified incubator at 37uCwith 5%
CO2 and 70% relative humidity. SK-BR3 parental and four clones were grown in
RPMI-1640 (Invitrogen, Carlsbad, California) with 10% FBS (Invitrogen, Carlsbad,
California), penicillin and streptomycin (BioWhittaker, Basel, Switzerland). The
resistance clones were cultured in the presence of additional 200 mg/mL Herceptin.
BT-474, MCF7-WT, MCF7-Her2 and HeLa cells were grown in DMEM (Invitrogen,
Carlsbad, California) with 10% FBS, penicillin and streptomycin. MCF7-Her2 cells
were cultured in the presence of 1 mg/mL puromycin. Cells were passaged with 0.05%
trypsin and 0.02% ethylenediaminetetraacetic acid in a Hank’s balanced salt solution
(Sigma-Aldrich, St Louis, Missouri) when they were approximately 75% confluent.
The cells were fixed prior to the kinetic measurement in order to minimize noises
caused by the micromotions of live cells. The fixation to cells was performed by
incubating with a 4% paraformaldehyde solution for 15 minutes at room
temperature.
SPRi setup.Themeasurement was carried out with homemade SPR imaging setup, in
which p-polarized light from a 670 nm light-emitting diode (L7868-01, Hamamatsu,
Japan) was directed through a triangle SF-11 prism onto the gold-coated BK-7 glass
(chip) placed on the prism. The LED light source was mounted on a temperature-
controlled mounting socket (LDM21, Thorlabs, Newton, USA). The reflected beam
produced an SPR image, which was captured by a CCD camera (Pike F032B, Allied
Vision Technology, Newburyport, USA). The optics included 103 magnification,
allowing for imaging of multiple individual cells. A Flexi-Perm silicon sample cell
(Greiner Bio-One) was placed on top of the gold chip to for cell culture. To promote
cell adhesion, each gold chip wasmodified with a collagen layer by incubating the chip
in 50 mL of 10 mg/mL collagen solution for 2 hours. The chip was then rinsed with
deionized water twice prior to cell seeding using 5,000 cells in 250 mL of growth
medium. To allow the cells to attach and grow on the chip surface, the chip was
incubated in the growth medium for 3 days. The growth medium was then replaced
with PBS buffer solution, and the cells were fixed by 4% paraformaldehyde solution
before each for binding kinetics experiment. All the SPR measurements were
performed at room temperature (,25uC).
Immunofluorescence. The immunofluorescence images were obtained at an
inverted fluorescence microscope at 603 (Fig. 5B only) or 103 (otherwise)
magnification (Olympus IX81). A 150 Wmercury lamp was used as the light source.
For Her2 staining, the fixed cells were incubated with 10 mg/mL Herceptin solution
for 30 minutes, followed by another 30 minutes incubation with Alexa Fluor 488 goat
anti-human IgG1 (c1) after 3 times rinses with PBS at room temperature. A
commercial anti-Her2 polyclonal antibody from rabbit (#2242, Cell Signaling
Technology) and corresponding Alexa Fluor 488 goat anti-rabbit IgG (A-11008, Life
Technologies) were used in Fig. S6. The fluorescence image was captured after the
well was rinsed twice by PBS buffer. A set of optical filters (Ex420-480/Em515) was
applied for Her2 staining. For MUC4 immunofluorescence, the fixed cells were
incubated withMUC4mousemAb (clone 1G8) for 30minutes, then rinsed 3 times in
PBS, followed by the incubation with Alexa Fluor 555 goat anti-mouse IgG1 (c1) for
another 30 minutes at room temperature. The fluorescence image was captured after
the well was rinsed twice by PBS buffer. A set of optical filters (Ex535/Em565) was
applied for MUC4 immunofluorescence.
Flow system. A gravity-based multichannel drug perfusion system (SF-77B, Warner
Instruments, Connecticut) was used to control the local solution that surrounded the
target cell. The typical transition time between different solutions was about 1–2
seconds.
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